All News
Methotrexate Monitoring (5.13.2022)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.
Read Article
A Day in the Life: Consults with a Rheumatology Fellow
d
MedPage Today
Join medical resident Siobhan Deshauer, MD, as she visits three hospitals for inpatient rheumatology.
Read Article
Can You Reduce Frequency of Methotrexate Monitoring?
Observational research presented at the British Society for Rheumatology meeting suggest that, based on the COVID-19 pandemic experience, reduced frequency of routine lab monitoring in patients receiving weekly methotrexate therapy for rheumatoid arthritis (RA) was not associated with an increase in adverse outcomes.
Read Article
Can You Reduce Frequency of Methotrexate Monitoring?
https://t.co/TnXZVCTv10 https://t.co/4q8sWwQ5aC
Links:
Dr. John Cush RheumNow ( View Tweet)
Wiki Guidelines Approach to Pyogenic Osteomyelitis
https://t.co/PaYolXmPv3 https://t.co/AXrwhRjQs4
Links:
Dr. John Cush RheumNow ( View Tweet)
Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis
This study identified genetic risk variants from genome-wide association analysis of OA patients to calculate PRSs associated with subsequent need for joint replacement surgery.
https://t.co/ZhAiuFu8iw https://t.co/OsR6p9m2S9
Links:
Dr. John Cush RheumNow ( View Tweet)
Lumbar spinal stenosis affects 103 million worldwide (11% of older adults in US). 1st line Rx is activity modification, analgesia, PT. Benefits of epidural steroids havent been established. Decompressive surgery only for selected pts w/ pain & limitation https://t.co/qdC8VXC1ko https://t.co/C67sB6IFVL
Links:
Dr. John Cush RheumNow ( View Tweet)
NEJM has published results of 2 phase 3 trials (BRAVE-AA1, BRAVE-AA2) demonstrating the efficacy of Baricitinib in aduls with severe alopecia areata - BARI was superior to placebo in hair regrowth by week 36 https://t.co/I88bvuU4cg https://t.co/4xNH0IZnGA
Links:
Dr. John Cush RheumNow ( View Tweet)
Small RCT 39 pts with #PMR given tocilizumab or placebo. Steroid-free remission at wk 16 was 64% on tocilizumab (63.2%) and 12% placebo. Mean time to first relapse was shorter with PBO (82 vs 130days). 5 SAE PBO, 1 TCZ https://t.co/FJjDxm7wfQ https://t.co/EiuSGaXgeh
Links:
Dr. John Cush RheumNow ( View Tweet)
Acne with JAK Inhibitors
JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi.
https://t.co/ADzaBjgsAN https://t.co/Yydo47UGYl
Links:
Dr. John Cush RheumNow ( View Tweet)
Welcome to the latest update from #SLEEducatorsNetwork, with Dr. Askanase, Director of the Lupus Center @Columbia who explains why a deeper understanding of SLE pathophysiology may help us better address its underlying mechanisms. Sponsored by GSK USMA.
https://t.co/LFfZAFgMWE https://t.co/n8X45pInYQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were given PBO or UPA (15 or 30 mg). 52 wk UPA achieved CDAI (37% & 48% vs 15% PBO)& endoscopic remission (28% & 40% vs 7%) https://t.co/eo2KtNOUW8 https://t.co/MKnTxVEkth
Links:
Dr. John Cush RheumNow ( View Tweet)
2019 Gabapentin Rx=69 million; 7th most common Rx in USA. MMWR: 62,652 overdose deaths, 52% had Pos. gabapentin test. OD deaths w/ GAB involved usually involved illicitly manufactured fentanyls. GAB+Opioids=BAD COMBO! https://t.co/qQbPmwzAgJ
Links:
Dr. John Cush RheumNow ( View Tweet)
EADV Dermatology Meeting presents data on the 2 year safety of Deucravacitinib, (TYK2 inhibitor); also showing DEUC is effective in scalp, nail, & palmoplantar PSO. Data from the phase 3 POETYK PSO-1 and PSO-2 trials https://t.co/cFz6XkpA69 https://t.co/ZNJzph6i5N https://t.co/QJZEhzqkY4
Dr. John Cush RheumNow ( View Tweet)
Welcome to the latest update from #SLEEducatorsNetwork, with Dr. Askanase, Director of the Lupus Center @Columbia who explains why a deeper understanding of SLE pathophysiology may help us better address its underlying mechanisms. Sponsored by GSK USMA.
https://t.co/spcdweO0pE https://t.co/0stEBPy6hc
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! Join us on May 17th for Tuesday Night Rheumatology on Spondyloarthritis Spectrum. This webinar will feature lecture highlights followed by live audience Q & A.
https://t.co/s7r09y5KNG https://t.co/0KYRPwGHsV
Links:
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab's Favorable Safety Profile in Psoriasis
A 2-year safety study of BMK, the dual IL-17A/F inhibitor, plaque psoriasis patients showed BMK, to be effective, well tolerated, w/ no new safety concerns other than a modest risk of oral candidiasis.
https://t.co/84zS8VET6B https://t.co/aLvLmmTc93
Links:
Dr. John Cush RheumNow ( View Tweet)
#ClinicalPearl Autoantibodies in #Sjogren’s Syndrome include CCP and anticentromere - think of overlaps with #rheumatoid arthritis or lcSSc limited cutaneous systemic sclerosis #scleroderma #CCR22 #CCR2022 @RheumNow https://t.co/vrdbv640B5
Janet Pope Janetbirdope ( View Tweet)
Risk factors for readmission among 132,400 #SLE hospitalizatiions included young SLE, AIHA (OR 1.86) GN (OR 1.41) pericarditis (OR 1.4), CHF(OR 1.38), Medicare (OR 1.2), Medicaid (OR 1.26). Most Readm Dxs were Sepsis, CHF, pneumonia https://t.co/Nr9bCGDaw0 https://t.co/THO6KT6dWV
Links:
Dr. John Cush RheumNow ( View Tweet)
Systemic Sclerosis patients with Digital Ulcers used significantly more healthcare resources per year. Study of 104 SSc pts; w/ DU's had more severe disease, more tests, More HCP/Rheum visits, etc (p˂0.05) https://t.co/wWvrOye92c https://t.co/HsZfSrf5CV
Links:
Dr. John Cush RheumNow ( View Tweet)